Maitake Mushroom and Metabolic Health: Beyond Blood Sugar

Mushrooms & Metabolic Health

30–80% reduction in triglycerides and cholesterol vs. controls

The 2024 comprehensive maitake review found consistent reductions in serum triglycerides, cholesterol, and phospholipids across multiple animal models, alongside documented blood pressure and gut microbiota effects.

Camilleri et al., Heliyon, 2024

4 domains

blood sugar, pressure, lipids, gut microbiota

SX-fraction

only maitake fraction tested for both glucose and blood pressure

3 studies

independently confirm maitake reshapes gut microbiota

Camilleri et al., Heliyon, 2024

View as image ↗

Most articles about maitake mushroom tell one story: it lowers blood sugar. A 2024 comprehensive review published in Heliyon found the evidence actually spans four separate metabolic domains — blood glucose, blood pressure, blood lipids, and gut microbiota composition.^[1] That breadth is unusual for a single food ingredient. Most of the evidence comes from animal models, which is a real limitation this article addresses directly. But the mechanistic detail that has accumulated across those studies is worth understanding, particularly for anyone trying to evaluate maitake's metabolic claims against the noise in the supplement space.

Maitake (Grifola frondosa) is uniquely documented to affect multiple metabolic syndrome markers: blood glucose via insulin sensitization and alpha-glucan fractions, blood pressure via the SX-fraction, blood lipids via hepatic fatty acid suppression, and gut microbiota composition via polysaccharide fermentation.

For how maitake compares to other mushroom species across the diabetes research landscape, the mushrooms for type 2 diabetes guide provides the species-level comparison.

The Mushroom With Four Metabolic Targets, Not One

Most mushrooms earn their metabolic reputation from a single angle. Reishi appears in lipid research. Cordyceps shows up in glucose uptake studies. Shiitake has accumulated cholesterol data.

Maitake has documented research across all four areas that define metabolic health: blood glucose, blood pressure, blood lipids, and gut microbiota composition. This isn't coincidence. It reflects an unusually varied portfolio of bioactive compounds, each targeting a different part of the metabolic system.

A 2021 review by Wu et al. in Foods catalogued maitake's active components:^[2] D-fraction (a beta-glucan most studied for immune activity), SX-fraction (a specialized extract with documented metabolic effects), MD-fraction (a standardized polysaccharide used in several clinical studies), distinct alpha-glucan fractions with their own antidiabetic activity, a glycoprotein that amplifies insulin function, and eritadenine (a sulfur-containing compound that affects lipid metabolism). Wu's review characterized maitake as having the broadest metabolic evidence base of any single culinary mushroom.

Each of these components acts through different mechanisms. The SX-fraction has been specifically studied for its simultaneous effects on both glucose and blood pressure. The alpha-glucan works through pathways distinct from the beta-glucan fractions. The glycoprotein does not directly lower blood sugar; it makes the insulin the body already produces work more effectively.

The 2024 comprehensive review by Camilleri et al. in Heliyon, the most recent authoritative maitake overview, summarized the full metabolic picture and documented maitake's capacity to suppress serum triglycerides, cholesterol, and phospholipids by 30-80% compared to controls across multiple animal studies.^[1] The range reflects genuine variation in dose, preparation, and animal model across studies, but the direction is consistent.

Blood Sugar: Three Mechanisms Running in Parallel

Most coverage of maitake and blood sugar treats it as a single story: maitake lowers glucose. The research is more specific than that. At least three distinct mechanisms have been documented in preclinical work, and they each work differently.

Insulin Sensitization, Not Just Glucose Lowering

In 2002, Manohar et al. gave a water-soluble maitake extract to KK mice, a strain bred to develop severe insulin resistance.^[3] The extract lowered both fasting glucose and fasting insulin.

That combination is the meaningful part. When something simply pushes the pancreas to make more insulin, you expect insulin levels to rise while glucose falls. Both going down together indicates something different: the body's cells became more responsive to the insulin already present, so less insulin was needed to keep blood sugar in check. Researchers call this insulin sensitization, and it is mechanistically distinct from insulin secretion stimulation.

The Alpha-Glucan Fraction's Independent Activity

In 2007, Hong et al. isolated maitake's alpha-glucan fraction specifically and tested it in KK-Ay mice, a model for spontaneous type 2 diabetes.^[4] The alpha-glucan showed significant antidiabetic activity on its own.

This is a point that most maitake coverage misses. The mushroom's antidiabetic activity is not entirely attributable to its well-known beta-glucan content. The alpha-glucan fraction, which is chemically and structurally distinct, carries its own independent effect through a different pathway. Maitake's glucose-lowering capacity reflects multiple compound classes working in parallel.

A Glycoprotein That Amplifies Insulin Signaling

The third mechanism works from a different molecular direction. Preuss et al. in 2007 extracted a glycoprotein fraction from maitake and administered it to rats alongside standard insulin doses.^[5] The glycoprotein enhanced insulin's own blood-sugar-lowering effect. The researchers described this as amplification of endogenous insulin signaling.

This is distinct from the insulin-sensitizing effect described above. The glycoprotein does not change how responsive the cells are to insulin. It appears to make the insulin signal itself stronger, so that the same amount of insulin accomplishes more glucose uptake.

The Molecular Relay Behind the Sensitization

In 2015, Xiao et al. traced the molecular mechanism behind maitake's insulin-sensitizing effect in diabetic rats, using specific polysaccharide fractions called F2 and F3.^[6] The improvement in insulin resistance worked through the PI3K/Akt signaling pathway.

To explain what that means without the jargon: inside every cell is a chain of molecular switches that carries the insulin signal from the cell's outer surface to the machinery that pulls glucose from the blood. When this chain is sluggish or broken, cells ignore insulin even when there is plenty of it circulating. That is the defining problem in type 2 diabetes. Maitake's F2 and F3 fractions restored normal function in this signaling chain. PI3K/Akt is the name of the specific molecular steps; the functional story is that maitake re-sensitized cells to insulin by repairing a broken signal relay.

For the human clinical trial evidence on maitake's specific fractions for blood sugar control, the maitake SX-fraction clinical trials covers that data in detail.

Blood Pressure: The Metabolic Benefit Nobody Mentions

Search for "maitake mushroom benefits" and blood pressure is almost never in the list. It has been in the research since 2002.

Talpur et al. tested whole maitake powder and its fractions in two rat strains, one of which was the Zucker fatty rat, an animal model developed specifically to study metabolic syndrome.^[7] In both strains, blood pressure and lipid profiles improved. The Zucker model is particularly relevant here because it replicates the clustered metabolic abnormalities that define metabolic syndrome in humans, not isolated blood pressure elevation alone.

In 2010, Preuss et al. ran a longer-term experiment in aging female rats.^[8] With age, these animals develop progressive hypertension alongside deteriorating glucose and lipid markers, mirroring the trajectory commonly seen in humans with advancing metabolic syndrome. Long-term maitake supplementation reversed the progression of both the hypertension and the metabolic deterioration. It did not just slow the worsening; it reversed the direction of change.

The SX-fraction is particularly relevant for blood pressure research. In 2012, Preuss et al. gave the SX-fraction to streptozotocin-induced diabetic rats and measured effects on both glucose and blood pressure.^[9] Both improved simultaneously. This dual-target effect from one specific fraction is what distinguishes SX-fraction research from most mushroom metabolic work, which tends to focus on one outcome at a time.

The practical limitation: all three of these studies are animal data. Whether the blood pressure effects seen in rat models translate to humans at realistic doses has not been tested in controlled human trials.

Cholesterol and Triglycerides: What Happens Inside the Liver

The Camilleri 2024 review documented 30-80% reductions in serum triglycerides, cholesterol, and phospholipids compared to controls across multiple animal studies.^[1] The range reflects genuine variation in dose and preparation methods, but the direction is consistent. What is less commonly reported is the mechanism, and the mechanism is where maitake's lipid story becomes specific.

In 2016, Ding et al. examined what maitake does inside the liver of rats fed high-fat diets.^[10] The liver is where most cholesterol and triglycerides are manufactured and where LDL particles are cleared from the blood. Ding found two specific molecular changes that maitake produced.

The first: maitake downregulated fatty acid synthase. This is the enzyme the liver uses to build new fat molecules from scratch. When this enzyme is less active, the liver produces less fat.

The second: maitake upregulated LDL receptor expression on liver cells. These receptors are proteins that grab LDL cholesterol particles from the bloodstream and pull them into the liver for processing and elimination. When there are more of these receptors, more LDL gets cleared from circulation.

Both changes go in the right direction for metabolic health, and they work through complementary pathways: less fat produced by the liver, and more cholesterol actively removed from the blood. This is a mechanistically specific story, not a vague "it improves cholesterol" claim.

As with the blood pressure data, this mechanism has been demonstrated in animal models. Whether the same molecular changes occur in humans at doses achievable from food or typical supplements is not yet established in published clinical research.

The Gut Microbiota Connection: Three Independent Studies, One Pattern

Between 2019 and 2020, three separate research groups published studies on maitake polysaccharides and gut bacteria in diabetic and high-fat diet animal models. All three found the same pattern.

Chen et al. in 2019 gave a novel maitake polysaccharide to type 2 diabetic mice.^[11] Blood glucose fell. When the researchers analyzed the gut bacteria, they found maitake had specifically increased Lactobacillus acidophilus and Bacteroides acidifaciens, two bacterial species associated with healthier metabolic states in the diabetes literature.

Li et al., also in 2019, studied maitake polysaccharides in rats fed a high-fat diet.^[12] They found simultaneous correction of lipid metabolic disorders and gut microbiota dysbiosis, the technical term for a gut bacterial community that has shifted away from a healthy balance. The gut ecosystem and the lipid markers moved in the right direction at the same time.

Guo et al. in 2020 went a step further and examined whether the gut microbiota changes and the metabolic improvements were statistically correlated with each other.^[13] They were. Maitake's blood sugar and lipid effects correlated directly with specific changes in intestinal microflora composition. Correlation does not prove causation, but finding the same pattern across three independent studies using different animal models, different polysaccharide preparations, and different research groups strengthens the case that the gut microbiota is a functional intermediary in maitake's metabolic activity.

The proposed mechanism works like this: maitake's polysaccharides are not broken down by digestive enzymes in the stomach or small intestine. They reach the colon intact, where the resident bacteria ferment them. That fermentation produces short-chain fatty acids. Short-chain fatty acids activate receptors on intestinal cells, triggering metabolic signaling that reaches the liver, the pancreas, and appetite-regulating pathways throughout the body.

For a detailed look at how this fermentation pathway connects to gut hormones like GLP-1 and ghrelin specifically, the article on how mushroom polysaccharides affect gut hormones and appetite maps that full signaling chain. The related pieces on mushrooms and the GLP-1 question and mushroom compounds and incretin hormones cover how these gut signals translate into insulin-related effects.

What the Evidence Shows and Where It Stops

This is a substantial body of preclinical research pointing in a consistent direction. The limitation is that it is almost entirely from animal models.

For blood sugar, maitake has progressed furthest toward human evidence. Clinical trials have been conducted on specific maitake fractions, particularly the SX-fraction, for glycemic outcomes in people with impaired glucose tolerance or type 2 diabetes. The maitake SX-fraction clinical trials covers that human data specifically.

For blood pressure effects in humans, the evidence remains limited to the animal studies described above. No powered human randomized controlled trial on maitake's antihypertensive activity has been published at the time of writing.

For cholesterol and triglycerides in humans, Ding's 2016 mechanistic data is compelling at the molecular level but unconfirmed in human lipid endpoint trials.

For gut microbiota, the three converging animal studies (Chen 2019, Li 2019, Guo 2020) are notable for their convergence, but controlled human gut microbiota studies using maitake have not been published.

The honest summary: maitake's metabolic research is more mechanistically specific than most dietary supplement research, and the convergence across animal models from multiple independent groups is notable. For most of the domains covered here, the translation from animal model to human clinical outcome remains to be validated.

For a broader view of how maitake's evidence compares to other mushrooms across the metabolic literature, the mushroom species comparison for diabetes management provides that context. For the full picture of how mushrooms address each of the five formal metabolic syndrome criteria, the mushrooms and metabolic syndrome article organizes the evidence by criterion with the species most supported for each.

The Bottom Line

Maitake (Grifola frondosa) has accumulated mechanistically specific research across four metabolic domains: blood glucose (via insulin sensitization, alpha-glucan fractions, and a glycoprotein that amplifies insulin signaling), blood pressure (via the SX-fraction and long-term supplementation in rat models), blood lipids (via hepatic fatty acid synthase downregulation and LDL receptor upregulation), and gut microbiota composition (three independent studies finding correlated improvements). Most of this evidence is from animal models. Human clinical data exists primarily for glycemic outcomes via specific maitake fractions, not for the other three domains.

Frequently Asked Questions

Is maitake mushroom good for metabolic syndrome?

Animal research documents maitake affecting multiple metabolic syndrome criteria simultaneously, including blood glucose, blood pressure, and lipid levels. No human randomized controlled trial has tested maitake specifically against the full five-criteria definition of metabolic syndrome. The human evidence that exists focuses on glycemic outcomes using specific maitake fractions. For the broader mushroom and metabolic syndrome evidence base, including which mushrooms are most supported for each of the five criteria, see the mushrooms and metabolic syndrome guide.

How does maitake lower blood pressure?

The mechanism in humans has not been established. In rat models, maitake's SX-fraction reduced blood pressure alongside blood glucose (Preuss et al., 2012), and long-term supplementation reversed hypertension progression in aging rats (Preuss et al., 2010). The Zucker fatty rat study by Talpur et al. (2002) also found blood pressure improvement alongside lipid benefits in an animal model of metabolic syndrome. What specific compounds and doses drive these effects in humans has not been determined in controlled clinical trials.

Does maitake mushroom reduce cholesterol?

In animal studies, maitake consistently reduced total cholesterol, LDL cholesterol, and triglycerides. A 2024 comprehensive review by Camilleri et al. reported 30-80% reductions in triglycerides and cholesterol compared to controls across multiple animal studies. The mechanism involves two changes in the liver: downregulation of fatty acid synthase (the enzyme that manufactures fat) and increased expression of LDL receptors (which pull LDL out of the blood for elimination). Human clinical evidence for these lipid effects has not been established in published trials.

What is the SX-fraction of maitake?

The SX-fraction is a standardized extract from maitake mushroom that combines specific polysaccharides and other bioactive compounds in a defined ratio. It is the most-studied maitake fraction for metabolic effects and is the subject of the most controlled maitake research for both blood glucose and blood pressure outcomes. For the specific human clinical trial data on the SX-fraction for glycemic control, the maitake SX-fraction clinical trials article covers those findings and the doses tested.

Is maitake better than other mushrooms for metabolic health?

Maitake has the broadest documented mechanistic evidence base across metabolic domains of any single culinary mushroom, as characterized by Wu et al. in their 2021 review. Head-to-head human comparisons have not been conducted. Reishi has stronger evidence in lipid meta-analyses specifically. Cordyceps has more human data on glucose uptake in athletes. Which mushroom is most supported depends on which metabolic outcome is being compared and in which population. The mushroom species comparison for metabolic health maps the evidence across species directly.

How much maitake should you take for blood sugar?

Human trials have used varying doses and preparation forms of maitake, making a single answer difficult. The SX-fraction studies provide the most controlled human data for glycemic effects, with specific dose information tied to measured outcomes. The maitake SX-fraction clinical trials article details the doses tested, the populations studied, and what was measured. Dose, form (whole mushroom vs. dried powder vs. specific fraction), and standardization all affect outcomes in the research, and no consensus clinical dose has been established.

Sources & References

1. 1RTHM-01862·Camilleri, Emma et al. (2024). “Unveiling the full spectrum of maitake mushrooms: A comprehensive review of their medicinal, therapeutic, nutraceutical, and cosmetic potential..” Heliyon.Study breakdown →PubMed →↩
2. 2RTHM-01455·Wu, Jian-Yong et al. (2021). “Bioactive Ingredients and Medicinal Values of Grifola frondosa (Maitake)..” Foods (Basel.Study breakdown →PubMed →↩
3. 3RTHM-00097·Manohar, V et al. (2002). “Effects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice..” Diabetes.Study breakdown →PubMed →↩
4. 4RTHM-00113·Hong, Lei et al. (2007). “Anti-diabetic effect of an alpha-glucan from fruit body of maitake (Grifola frondosa) on KK-Ay mice..” The Journal of pharmacy and pharmacology.Study breakdown →PubMed →↩
5. 5RTHM-00229·Preuss, Harry G et al. (2007). “Enhanced insulin-hypoglycemic activity in rats consuming a specific glycoprotein extracted from maitake mushroom..” Molecular and cellular biochemistry.Study breakdown →PubMed →↩
6. 6RTHM-00410·Xiao, Chun et al. (2015). “Hypoglycemic effects of Grifola frondosa (Maitake) polysaccharides F2 and F3 through improvement of insulin resistance in diabetic rats..” Food & function.Study breakdown →PubMed →↩
7. 7RTHM-00053·Talpur, Nadeem A et al. (2002). “Antihypertensive and metabolic effects of whole Maitake mushroom powder and its fractions in two rat strains..” Molecular and cellular biochemistry.Study breakdown →PubMed →↩
8. 8RTHM-00196·Preuss, Harry G et al. (2010). “Maitake mushroom extracts ameliorate progressive hypertension and other chronic metabolic perturbations in aging female rats..” International journal of medical sciences.Study breakdown →PubMed →↩
9. 9RTHM-00262·Preuss, Harry G et al. (2012). “Fraction SX of maitake mushroom favorably influences blood glucose levels and blood pressure in streptozotocin-induced diabetic rats..” Journal of medicinal food.Study breakdown →PubMed →↩
10. 10RTHM-00778·Ding, Yinrun et al. (2016). “The Mechanisms Underlying the Hypolipidaemic Effects of Grifola frondosa in the Liver of Rats..” Frontiers in microbiology.Study breakdown →PubMed →↩
11. 11RTHM-01042·Chen, Yuqing et al. (2019). “Hypoglycemic activity and gut microbiota regulation of a novel polysaccharide from Grifola frondosa in type 2 diabetic mice..” Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.Study breakdown →PubMed →↩
12. 12RTHM-01084·Li, Lu et al. (2019). “Grifola frondosa polysaccharides ameliorate lipid metabolic disorders and gut microbiota dysbiosis in high-fat diet fed rats..” Food & function.Study breakdown →PubMed →↩
13. 13RTHM-01193·Guo, Wei-Ling et al. (2020). “Hypoglycemic and hypolipidemic activities of Grifola frondosa polysaccharides and their relationships with the modulation of intestinal microflora in diabetic mice induced by high-fat diet and streptozotocin..” International journal of biological macromolecules.Study breakdown →PubMed →↩